Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) is set to issue its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.29) per share for the quarter. Investors that wish to listen to the company's conference call can do so using this link.
Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.18). On average, analysts expect Mind Medicine (MindMed) to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Mind Medicine (MindMed) Price Performance
NASDAQ:MNMD traded up $0.01 during mid-day trading on Thursday, reaching $6.35. The stock had a trading volume of 545,197 shares, compared to its average volume of 1,395,690. Mind Medicine has a 12 month low of $2.41 and a 12 month high of $12.22. The stock has a 50-day simple moving average of $5.99 and a two-hundred day simple moving average of $7.35. The company has a debt-to-equity ratio of 0.12, a current ratio of 5.92 and a quick ratio of 5.92. The stock has a market capitalization of $458.12 million, a PE ratio of -2.54 and a beta of 2.52.
Analyst Ratings Changes
Several research analysts have recently issued reports on MNMD shares. Canaccord Genuity Group lowered their price target on shares of Mind Medicine (MindMed) from $16.00 to $14.00 and set a "buy" rating for the company in a report on Monday, September 16th. HC Wainwright increased their target price on Mind Medicine (MindMed) from $35.00 to $55.00 and gave the company a "buy" rating in a research report on Thursday, August 29th. Leerink Partnrs raised Mind Medicine (MindMed) to a "strong-buy" rating in a research note on Friday, October 11th. Roth Capital upgraded shares of Mind Medicine (MindMed) to a "strong-buy" rating in a research report on Wednesday, July 24th. Finally, Roth Mkm initiated coverage on shares of Mind Medicine (MindMed) in a research note on Wednesday, July 24th. They issued a "buy" rating and a $36.00 price objective on the stock. Nine analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $25.38.
View Our Latest Stock Analysis on MNMD
Insider Transactions at Mind Medicine (MindMed)
In related news, insider Dan Karlin sold 6,871 shares of the company's stock in a transaction that occurred on Wednesday, September 25th. The stock was sold at an average price of $5.98, for a total value of $41,088.58. Following the transaction, the insider now owns 344,656 shares in the company, valued at approximately $2,061,042.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Robert Barrow sold 19,771 shares of Mind Medicine (MindMed) stock in a transaction dated Wednesday, September 25th. The stock was sold at an average price of $5.98, for a total transaction of $118,230.58. Following the completion of the sale, the chief executive officer now owns 545,772 shares in the company, valued at approximately $3,263,716.56. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Dan Karlin sold 6,871 shares of the business's stock in a transaction that occurred on Wednesday, September 25th. The stock was sold at an average price of $5.98, for a total transaction of $41,088.58. Following the completion of the transaction, the insider now directly owns 344,656 shares of the company's stock, valued at approximately $2,061,042.88. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 28,994 shares of company stock worth $173,384 in the last ninety days. Company insiders own 2.26% of the company's stock.
About Mind Medicine (MindMed)
(
Get Free Report)
Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.
Read More
Before you consider Mind Medicine (MindMed), you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mind Medicine (MindMed) wasn't on the list.
While Mind Medicine (MindMed) currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
